D
International Stem Cell Corporation
ISCO
$0.115
$0.02527.78%
D
Sell
3/3/2025Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D- from E on 3/3/2025 due to an increase in the total return index and volatility index.
International Stem Cell Corporation (ISCO) was upgraded to D- from E on 3/3/2025 due to an increase in the total return index and volatility index.
E
Sell
12/2/2024Upgraded
International Stem Cell Corporation (ISCO) was upgraded to E from E- on 12/2/2024 due to an increase in the volatility index, solvency index and total return index.
International Stem Cell Corporation (ISCO) was upgraded to E from E- on 12/2/2024 due to an increase in the volatility index, solvency index and total return index.
E
Sell
8/27/2024Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E- from E+ on 8/27/2024 due to a decline in the solvency index.
International Stem Cell Corporation (ISCO) was downgraded to E- from E+ on 8/27/2024 due to a decline in the solvency index.
E
Sell
4/11/2024Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 4/11/2024 due to a substantial decline in the efficiency index, growth index and volatility index. EBIT declined 337.11% from -$97 to -$424, net income declined 249.62% from -$131 to -$458, and earnings per share declined from -$0.0164 to -$0.0379.
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 4/11/2024 due to a substantial decline in the efficiency index, growth index and volatility index. EBIT declined 337.11% from -$97 to -$424, net income declined 249.62% from -$131 to -$458, and earnings per share declined from -$0.0164 to -$0.0379.
D
Sell
8/14/2023Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D from E+ on 8/14/2023 due to a substantial increase in the efficiency index, growth index and solvency index. Net income increased 1,547.06% from -$34 to $492, earnings per share increased from -$0.0042 to $0.0324, and operating cash flow increased 126.85% from $216 to $490.
International Stem Cell Corporation (ISCO) was upgraded to D from E+ on 8/14/2023 due to a substantial increase in the efficiency index, growth index and solvency index. Net income increased 1,547.06% from -$34 to $492, earnings per share increased from -$0.0042 to $0.0324, and operating cash flow increased 126.85% from $216 to $490.
E
Sell
3/14/2023Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E+ from D- on 03/14/2023.
International Stem Cell Corporation (ISCO) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D- from E+ on 02/23/2023.
International Stem Cell Corporation (ISCO) was upgraded to D- from E+ on 02/23/2023.
E
Sell
2/8/2023Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
International Stem Cell Corporation (ISCO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index and volatility index.
D
Sell
11/21/2022Downgrade
International Stem Cell Corporation (ISCO) was downgraded to D- from D on 11/21/2022 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0002 to -$0.0429, EBIT declined 1,067.74% from $31 to -$300, and operating cash flow declined 56.25% from $192 to $84.
International Stem Cell Corporation (ISCO) was downgraded to D- from D on 11/21/2022 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0002 to -$0.0429, EBIT declined 1,067.74% from $31 to -$300, and operating cash flow declined 56.25% from $192 to $84.
D
Sell
5/16/2022Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D from E+ on 5/16/2022 due to a significant increase in the growth index. EBIT increased 107.74% from -$323 to $25, earnings per share increased from -$0.0438 to -$0.0011, and operating cash flow increased 92.72% from -$316 to -$23.
International Stem Cell Corporation (ISCO) was upgraded to D from E+ on 5/16/2022 due to a significant increase in the growth index. EBIT increased 107.74% from -$323 to $25, earnings per share increased from -$0.0438 to -$0.0011, and operating cash flow increased 92.72% from -$316 to -$23.
E
Sell
5/13/2022Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
International Stem Cell Corporation (ISCO) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index.
International Stem Cell Corporation (ISCO) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/20/2022Downgrade
International Stem Cell Corporation (ISCO) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
International Stem Cell Corporation (ISCO) was downgraded to D- from D on 4/20/2022 due to a decline in the valuation index.
D
Sell
3/31/2022Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D from D- on 3/31/2022 due to an increase in the growth index, total return index and volatility index. EBIT increased 48.15% from -$623 to -$323, and total revenue increased 0.05% from $1.84M to $1.84M.
International Stem Cell Corporation (ISCO) was upgraded to D from D- on 3/31/2022 due to an increase in the growth index, total return index and volatility index. EBIT increased 48.15% from -$623 to -$323, and total revenue increased 0.05% from $1.84M to $1.84M.
D
Sell
11/15/2021Downgrade
International Stem Cell Corporation (ISCO) was downgraded to D- from D on 11/15/2021 due to a significant decline in the growth index, volatility index and solvency index. Earnings per share declined from $0.0278 to -$0.0206, EBIT declined 53.45% from -$406 to -$623, and the quick ratio declined from 0.32 to 0.27.
International Stem Cell Corporation (ISCO) was downgraded to D- from D on 11/15/2021 due to a significant decline in the growth index, volatility index and solvency index. Earnings per share declined from $0.0278 to -$0.0206, EBIT declined 53.45% from -$406 to -$623, and the quick ratio declined from 0.32 to 0.27.
D
Sell
11/9/2021Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
International Stem Cell Corporation (ISCO) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 11/8/2021 due to a decline in the growth index, volatility index and total return index.
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 11/8/2021 due to a decline in the growth index, volatility index and total return index.
D
Sell
5/1/2020Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index.
International Stem Cell Corporation (ISCO) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index.
D
Sell
11/19/2018Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D- from E+ on 11/19/2018 due to an increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.0631 to $0.0191, debt to equity declined from 0.67 to 0, and the quick ratio increased from 0.31 to 0.46.
International Stem Cell Corporation (ISCO) was upgraded to D- from E+ on 11/19/2018 due to an increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.0631 to $0.0191, debt to equity declined from 0.67 to 0, and the quick ratio increased from 0.31 to 0.46.
E
Sell
8/24/2018Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 8/24/2018 due to a decline in the solvency index. Debt to equity increased from 0.21 to 0.67.
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 8/24/2018 due to a decline in the solvency index. Debt to equity increased from 0.21 to 0.67.
D
Sell
5/22/2018Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D from D- on 5/22/2018 due to an increase in the solvency index, total return index and volatility index. The quick ratio increased from 0.16 to 0.24.
International Stem Cell Corporation (ISCO) was upgraded to D from D- on 5/22/2018 due to an increase in the solvency index, total return index and volatility index. The quick ratio increased from 0.16 to 0.24.
D
Sell
11/24/2017Downgrade
International Stem Cell Corporation (ISCO) was downgraded to D- from D+ on 11/24/2017 due to a significant decline in the efficiency index.
International Stem Cell Corporation (ISCO) was downgraded to D- from D+ on 11/24/2017 due to a significant decline in the efficiency index.
D
Sell
11/15/2017Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D+ from D on 11/15/2017 due to an increase in the valuation index, total return index and efficiency index.
International Stem Cell Corporation (ISCO) was upgraded to D+ from D on 11/15/2017 due to an increase in the valuation index, total return index and efficiency index.
D
Sell
5/17/2017Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D from D- on 5/17/2017 due to a significant increase in the efficiency index, growth index and total return index. Operating cash flow increased 39.19% from -$939 to -$571, total revenue increased 18.64% from $1.69M to $2.01M, and EBIT increased 8.96% from -$1.15M to -$1.05M.
International Stem Cell Corporation (ISCO) was upgraded to D from D- on 5/17/2017 due to a significant increase in the efficiency index, growth index and total return index. Operating cash flow increased 39.19% from -$939 to -$571, total revenue increased 18.64% from $1.69M to $2.01M, and EBIT increased 8.96% from -$1.15M to -$1.05M.
D
Sell
3/31/2017Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D- from E+ on 3/31/2017 due to an increase in the valuation index and solvency index. The quick ratio increased from 0.19 to 0.19.
International Stem Cell Corporation (ISCO) was upgraded to D- from E+ on 3/31/2017 due to an increase in the valuation index and solvency index. The quick ratio increased from 0.19 to 0.19.
E
Sell
11/17/2016Downgrade
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 11/17/2016 due to a significant decline in the growth index and valuation index. Earnings per share declined from $0.26 to -$0.3, and EBIT declined 1.2% from -$1.25M to -$1.26M.
International Stem Cell Corporation (ISCO) was downgraded to E+ from D on 11/17/2016 due to a significant decline in the growth index and valuation index. Earnings per share declined from $0.26 to -$0.3, and EBIT declined 1.2% from -$1.25M to -$1.26M.
D
Sell
3/11/2016Downgrade
International Stem Cell Corporation (ISCO) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the volatility index, total return index and solvency index.
International Stem Cell Corporation (ISCO) was downgraded to D from D+ on 3/11/2016 due to a substantial decline in the volatility index, total return index and solvency index.
D
Sell
11/13/2015Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D+ from D- on 11/13/2015 due to a noticeable increase in the growth index and solvency index. Debt to equity declined from 2.83 to 0, the quick ratio increased from 0.15 to 0.19, and total revenue increased 17.69% from $1.82M to $2.14M.
International Stem Cell Corporation (ISCO) was upgraded to D+ from D- on 11/13/2015 due to a noticeable increase in the growth index and solvency index. Debt to equity declined from 2.83 to 0, the quick ratio increased from 0.15 to 0.19, and total revenue increased 17.69% from $1.82M to $2.14M.
D
Sell
8/21/2015Downgrade
International Stem Cell Corporation (ISCOD) was downgraded to D- from D+ on 8/21/2015 due to a decline in the solvency index and valuation index.
International Stem Cell Corporation (ISCOD) was downgraded to D- from D+ on 8/21/2015 due to a decline in the solvency index and valuation index.
D
Sell
8/17/2015Downgrade
International Stem Cell Corporation (ISCOD) was downgraded to D+ from C on 8/17/2015 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 1,118.99% from -$79 to $805, net income declined 156.18% from -$1.29M to $723, and earnings per share declined from -$1.5 to $0.3844.
International Stem Cell Corporation (ISCOD) was downgraded to D+ from C on 8/17/2015 due to a significant decline in the efficiency index, valuation index and growth index. Total capital declined 1,118.99% from -$79 to $805, net income declined 156.18% from -$1.29M to $723, and earnings per share declined from -$1.5 to $0.3844.
C
Hold
5/11/2015Upgraded
International Stem Cell Corporation (ISCO) was upgraded to C from D+ on 5/11/2015 due to a significant increase in the efficiency index, volatility index and valuation index.
International Stem Cell Corporation (ISCO) was upgraded to C from D+ on 5/11/2015 due to a significant increase in the efficiency index, volatility index and valuation index.
D
Sell
11/21/2014Upgraded
International Stem Cell Corporation (ISCO) was upgraded to D+ from D on 11/21/2014 due to a large increase in the growth index and solvency index. Total revenue increased 23.61% from $1.59M to $1.96M.
International Stem Cell Corporation (ISCO) was upgraded to D+ from D on 11/21/2014 due to a large increase in the growth index and solvency index. Total revenue increased 23.61% from $1.59M to $1.96M.
D
Sell
5/14/2014Downgrade
International Stem Cell Corporation (ISCO) was downgraded to D from D+ on 5/14/2014 due to a decline in the growth index and solvency index. Earnings per share declined from -$0.0187 to -$0.01, the quick ratio declined from 0.36 to 0.25, and total revenue declined 4.96% from $1.74M to $1.65M.
International Stem Cell Corporation (ISCO) was downgraded to D from D+ on 5/14/2014 due to a decline in the growth index and solvency index. Earnings per share declined from -$0.0187 to -$0.01, the quick ratio declined from 0.36 to 0.25, and total revenue declined 4.96% from $1.74M to $1.65M.
OTC PK
03/07/2025 3:48PM Eastern
Quotes delayed
